ALVONasdaq

Alvotech

Biological Products, (No Diagnostic Substances) · N4 · CIK 1898416

Alvotech develops and manufactures biosimilar medicines for global patient access and healthcare sustainability

+ Watch View on EDGAR ↗

$1.22B

Market cap

$3.28

Last close

-1.2%

-9.1%

398K

Volume

Price$3.28-62.4%· 1Y

Volume

Jul 10L $3.00 · H $9.81Jul 10

Revenue & earnings

RevenueNet incomeLoss

Fundamentals & quality

Trailing fundamentals · via Polygon & SEC

Rev growth YoY

19.7%

Trailing 12 months

Gross margin

59.8%

Gross profit / revenue

Net margin

4.8%

Net income / revenue

ROE

—

Return on equity

ROIC

5.2%

Return on invested capital

FCF yield

-9.4%

Free cash flow / mkt cap

P/E

43.7

Price / earnings

P/S

2.1

Price / sales

Similar companies

Comparable business profile · signals at a glance

ALLOAllogene Therapeutics, Inc.$717.9M-4.8%AVTXAvalo Therapeutics, Inc.$990.3M-3.7%ALDXAldeyra Therapeutics, Inc.$136.9M-10.0%ATRAAtara Biotherapeutics, Inc.$105.0M-1.9%ZLABZai Lab Ltd

Filings archive

Newest first · each with a one-line AI read · showing 10 of 182

Jun 30, 2026SC 13D/ASC 13D/A Jun 18, 20266-KFORM 6-KAlvotech announced the closing of its underwritten public offering and the full exercise of the underwriters' option to purchase additional ordinary shares.Jun 17, 20266-K6-KAlvotech raised approximately $91.20 million in net proceeds from a public offering of ordinary shares and an additional $66.85 million from a private placement of ordinary shares. The company also received Complete Response Letters from the FDA for its Biologics License Applications (BLAs) for AVT03, AVT05, and AVT06, citing deficiencies related to its Reykjavik manufacturing facility.